<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492921</url>
  </required_header>
  <id_info>
    <org_study_id>J06116</org_study_id>
    <secondary_id>P01CA015396</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>NA_00003256</secondary_id>
    <nct_id>NCT00492921</nct_id>
  </id_info>
  <brief_title>High-Dose Cyclophosphamide for Steroid Refractory GVHD</brief_title>
  <official_title>High-Dose Cyclophosphamide in Treating Patients With Acute Graft-Versus-Host Disease That Did Not Respond to Steroid Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: High-dose cyclophosphamide may be an effective treatment for acute
      graft-versus-host disease that did not respond to steroid therapy.

      PURPOSE: This phase II trial is studying the side effects, best dose, and how well high-dose
      cyclophosphamide works in treating patients with acute graft-versus-host disease that did not
      respond to steroid therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of high-dose cyclophosphamide in patients with
           steroid refractory acute graft-versus-host disease (GVHD).

        -  Determine the efficacy of this regimen at 28 days post-treatment in these patients.

      OUTLINE: This is a dose-escalation study.

      Patients receive high-dose cyclophosphamide once daily for 1-4 days beginning on day 1 and
      filgrastim (G-CSF) subcutaneously once daily beginning on day 10 and continuing until blood
      counts recover.

      Cohorts of 3-6 patients receive escalating doses of high-dose cyclophosphamide until the
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

      After completion of study treatment, patients are followed weekly for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of High-dose Cyclophosphamide as Determined by Number of Participants Who Tolerated Each Dose of Cyclophosphamide</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GVHD Response Rate</measure>
    <time_frame>Day 28</time_frame>
    <description>Percentage of patients whose GVHD (as defined by Przepiorka criteria) responded to cyclophosphamide (complete response). Acute GVHD is defined by the Przepiorka criteria, which stages the degree of organ involvement in the skin, liver, and gastrointestinal (GI) tract, based on severity, with Stage 1+ being least severe and stage 4+ being the most severe. Grading of acute GVHD is as follows: Grade I (skin involvement stages 1+ to 2+, with no liver or GI involvement), Grade II (skin involvement stages 1+ to 3+, liver 1+, GI tract 1+), Grade III (skin involvement stages 2+ to 3+, liver 1+, GI tract 2+ to 4+), Grade IV (skin involvement stages 4+, Liver 4+).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide 50</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with cyclophosphamide 50 mg/kg/d x 1 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide 100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with cyclophosphamide 50 mg/kg/d x 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide 150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with cyclophosphamide 50 mg/kg/d x 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Cyclophosphamide 100</arm_group_label>
    <arm_group_label>Cyclophosphamide 150</arm_group_label>
    <arm_group_label>Cyclophosphamide 50</arm_group_label>
    <other_name>Cy</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed acute graft-versus-host disease (GVHD) ≥ clinical grade II,
             that is steroid refractory

               -  Steroid refractory GVHD is defined as GVHD that has progressed (increasing in
                  grading) despite 49 hours of treatment with methylprednisolone of ≥ 2.0 mg/kg OR
                  GVHD that has failed to improve (no change in grading stage) despite 4 days of
                  treatment with methylprednisolone of ≥ 2.0 mg/kg

          -  Prior allogeneic hematopoietic stem cell transplantation using either bone marrow,
             peripheral blood stem cells, or cord blood OR prior donor lymphocyte infusion required

          -  Evidence of myeloid engraftment

          -  No chronic GVHD

        PATIENT CHARACTERISTICS:

          -  ECOG (Eastern Cooperative Oncology Group) performance status (PS) 0-2 OR Karnofsky PS
             60-100%

          -  ANC (absolute neutrophil count) &gt; 500/mm³

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Must be geographically accessible

          -  No allergy or intolerance to cyclophosphamide or mesna

          -  No HIV positivity

          -  No mechanical ventilation

          -  No active bleeding (excluding gastrointestinal bleeding) or history of hemorrhagic
             cystitis

          -  No other uncontrolled illness including, but not limited to, the following:

               -  Ongoing or active infection

               -  Medical condition precluding patient from stopping azoles (e.g., fluconazole,
                  itraconazole, or voriconazole) or other adequate antifungal therapy during
                  cyclophosphamide administration

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Psychiatric illness/social situations that would preclude compliance

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Bolanos-Meade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <results_first_submitted>July 27, 2018</results_first_submitted>
  <results_first_submitted_qc>September 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2018</results_first_posted>
  <last_update_submitted>September 11, 2018</last_update_submitted>
  <last_update_submitted_qc>September 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cyclophosphamide 50 mg/kg</title>
          <description>Treatment with cyclophosphamide 50 mg/kg/d x 1 day.</description>
        </group>
        <group group_id="P2">
          <title>Cyclophosphamide 100 mg/kg</title>
          <description>Treatment with cyclophosphamide 50 mg/kg/d x 2 days.</description>
        </group>
        <group group_id="P3">
          <title>Cyclophosphamide 150 mg/kg</title>
          <description>Treatment with cyclophosphamide 50 mg/kg/d x 3 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study site prefers to describe the study population as one set due to very small sample sizes for each arm.</population>
      <group_list>
        <group group_id="B1">
          <title>Cyclophosphamide</title>
          <description>Treatment with cyclophosphamide 50 mg/kg/d x 2 days, then dose adjusted according to continuous reassessment model according to toxicities until MTD found.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="12" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose of High-dose Cyclophosphamide as Determined by Number of Participants Who Tolerated Each Dose of Cyclophosphamide</title>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyclophosphamide 50 mg/kg</title>
            <description>Treatment with cyclophosphamide 50 mg/kg/d x 1 day.</description>
          </group>
          <group group_id="O2">
            <title>Cyclophosphamide 100 mg/kg</title>
            <description>Treatment with cyclophosphamide 50 mg/kg/d x 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Cyclophosphamide 150 mg/kg</title>
            <description>Treatment with cyclophosphamide 50 mg/kg/d x 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose of High-dose Cyclophosphamide as Determined by Number of Participants Who Tolerated Each Dose of Cyclophosphamide</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GVHD Response Rate</title>
        <description>Percentage of patients whose GVHD (as defined by Przepiorka criteria) responded to cyclophosphamide (complete response). Acute GVHD is defined by the Przepiorka criteria, which stages the degree of organ involvement in the skin, liver, and gastrointestinal (GI) tract, based on severity, with Stage 1+ being least severe and stage 4+ being the most severe. Grading of acute GVHD is as follows: Grade I (skin involvement stages 1+ to 2+, with no liver or GI involvement), Grade II (skin involvement stages 1+ to 3+, liver 1+, GI tract 1+), Grade III (skin involvement stages 2+ to 3+, liver 1+, GI tract 2+ to 4+), Grade IV (skin involvement stages 4+, Liver 4+).</description>
        <time_frame>Day 28</time_frame>
        <population>This analysis excludes the two participants who died early because their responses were not assessed prior to death.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclophosphamide 50 mg/kg</title>
            <description>Treatment with cyclophosphamide 50 mg/kg/d x 1 day.</description>
          </group>
          <group group_id="O2">
            <title>Cyclophosphamide 100 mg/kg</title>
            <description>Treatment with cyclophosphamide 50 mg/kg/d x 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Cyclophosphamide 150 mg/kg</title>
            <description>Treatment with cyclophosphamide 50 mg/kg/d x 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GVHD Response Rate</title>
          <description>Percentage of patients whose GVHD (as defined by Przepiorka criteria) responded to cyclophosphamide (complete response). Acute GVHD is defined by the Przepiorka criteria, which stages the degree of organ involvement in the skin, liver, and gastrointestinal (GI) tract, based on severity, with Stage 1+ being least severe and stage 4+ being the most severe. Grading of acute GVHD is as follows: Grade I (skin involvement stages 1+ to 2+, with no liver or GI involvement), Grade II (skin involvement stages 1+ to 3+, liver 1+, GI tract 1+), Grade III (skin involvement stages 2+ to 3+, liver 1+, GI tract 2+ to 4+), Grade IV (skin involvement stages 4+, Liver 4+).</description>
          <population>This analysis excludes the two participants who died early because their responses were not assessed prior to death.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>every week through Day 30</time_frame>
      <desc>The following events only were collected per the protocol's definition of an adverse event: unexpected adverse events that were attributed to the study drug by the investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cyclophosphamide 50 mg/kg</title>
          <description>Treatment with cyclophosphamide 50 mg/kg/d x 1 day.</description>
        </group>
        <group group_id="E2">
          <title>Cyclophosphamide 100 mg/kg</title>
          <description>Treatment with cyclophosphamide 50 mg/kg/d x 2 days.</description>
        </group>
        <group group_id="E3">
          <title>Cyclophosphamide 150 mg/kg</title>
          <description>Treatment with cyclophosphamide 50 mg/kg/d x 3 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - abdomen</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Javier Bolanos Meade</name_or_title>
      <organization>JHU SKCCC</organization>
      <phone>410-614-6398</phone>
      <email>Fbolano2@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

